NCT02888704View on ClinicalTrials.gov

Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Atopic Dermatitis
Interventions
DRUG

ADSTEM Inj. (Adult human mesenchymal stem cells)

Comparison of different dosages of the drug in the aspect of safety and efficacy.

Trial Locations (1)

35015

Chungnam National University Hospital, Daejeon

All Listed Sponsors
lead

EHL Bio Co., Ltd.

INDUSTRY

NCT02888704 - Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis | Biotech Hunter | Biotech Hunter